October 13, 2021 | Highland, MD – The Jayne Koskinas Ted Giovanis Foundation for Health and Policy has extended prior JKTGF funded research to Heiko Enderling, Ph.D., a faculty member of Moffitt Cancer Center, to support his work personalizing radiation therapy to better fight breast cancer.
It is now widely recognized that breast cancer therapy should be tailored to individual patients. While patient-specific data has affected the decision for use of chemotherapy, it has yet to impact radiation therapy, the single most used therapeutic treatment in oncology.
This research seeks to decipher the architecture of the tumor-immune ecosystem in biopsy tissues to identify the optimal radiation protocol – on a per-patient basis – to induce robust immunity and eradicate the tumor.
“Radiation therapy is the most used therapy for fighting breast cancer, yet no clinical trials have attempted to individualize it,” said Ted Giovanis, founder and president of the JKTG Foundation.
“Heiko’s research has challenged current practice with exciting results, and the Foundation is pleased to further support his work so future breast cancer patients benefit from individualized treatment and better outcomes.”
Featured news
Ted’s Take: Medicare for all – HUH?
Around every national election, the phrase Medicare for All comes up. My reaction is simple: HUH? Here’s why?
JKTG-Funded Research Tackles Possible Way to Stop Spread of Breast Cancer
New JKTG Foundation-funded research identifies potential new immune system target to head off the spread of breast cancer cells. The work is from the Johns Hopkins Giovanis Institute and appears in the journal Oncogene.
Ted’s Take: Leaders and Leadership
We need more leaders; Government, businesses, consulting firms, fortune 500 companies, associations, you name it. The problem is there is a dearth of leaders, but few are truly able to take a leadership role.
Jayne Koskinas Ted Giovanis
Foundation for Health and Policy
PO Box 130
Highland, Maryland 20777
Media contact: 202.548.0133